In an attempt to bring patient-specific induced pluripotent stem cell (iPSCs) technology closer to the clinic, researchers have created iPSCs from patient-derived chondrocytes, using an non-integrative reprogramming method, and used these to then create large numbers of cartilage producing cells. This strategy takes advantage of the cells “somatic memory of origin” and novel reprogramming strategies to make these cells an effective and safe source of cells for the treatment of cartilage defects and osteoarthritis.
- Will functional testing of the derived cells prove them to be useful?
- Can we take advantage of the somatic memory of origin “problem” in other differentiation strategies?
- Can other non-integrative methods of reprogramming be utilised and inter-compared?
- What are the characteristics of the putative chondrogenic progenitor, and can we use these to create a purer, and more effective, cell population?